Gland Pharma Limited (BOM:543245)
India
· Delayed Price · Currency is INR 1,721.65
+13.25 (0.78%)
At close: Jun 20, 2025
Gland Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Net Income | 6,985 | 7,725 | 7,810 | 12,117 | 9,970 | Upgrade
|
| Depreciation & Amortization | 3,779 | 3,446 | 1,467 | 1,103 | 987.8 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.32 | -2.49 | 0.81 | 1.78 | -0.24 | Upgrade
|
| Asset Writedown & Restructuring Costs | 18.24 | - | 63.32 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -12.27 | -3.48 | -28.48 | -44.89 | - | Upgrade
|
| Stock-Based Compensation | - | - | - | 46.21 | 155.34 | Upgrade
|
| Provision & Write-off of Bad Debts | 46.23 | 214.21 | 22.04 | 41.27 | -25.85 | Upgrade
|
| Other Operating Activities | -1,609 | -878.54 | -1,516 | -1,426 | -679.8 | Upgrade
|
| Change in Accounts Receivable | 422.88 | -3,250 | 1,440 | -4,196 | -602.01 | Upgrade
|
| Change in Inventory | -199.18 | 6,661 | -7,596 | 895.01 | -5,189 | Upgrade
|
| Change in Accounts Payable | 269.03 | -3,789 | 1,210 | 659.19 | 1,384 | Upgrade
|
| Change in Other Net Operating Assets | -553.36 | -154.51 | 767.19 | -1,289 | 48.9 | Upgrade
|
| Operating Cash Flow | 9,147 | 9,968 | 3,640 | 7,908 | 6,049 | Upgrade
|
| Operating Cash Flow Growth | -8.23% | 173.87% | -53.97% | 30.72% | -13.70% | Upgrade
|
| Capital Expenditures | -3,845 | -3,899 | -2,209 | -5,113 | -2,288 | Upgrade
|
| Sale of Property, Plant & Equipment | 3.38 | 7.67 | 1.4 | 3.99 | 4.3 | Upgrade
|
| Cash Acquisitions | - | -10,218 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -96.24 | -83.26 | -21.9 | -107.92 | - | Upgrade
|
| Investment in Securities | 19,421 | -4,747 | 12,706 | -6,117 | -13,576 | Upgrade
|
| Other Investing Activities | 1,565 | 1,371 | 1,606 | 1,308 | 619.37 | Upgrade
|
| Investing Cash Flow | 17,047 | -17,569 | 12,082 | -10,026 | -15,240 | Upgrade
|
| Long-Term Debt Issued | 52.83 | 210.28 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -811.64 | -7,954 | -2.9 | -2.52 | -10.16 | Upgrade
|
| Total Debt Repaid | -811.64 | -7,954 | -2.9 | -2.52 | -10.16 | Upgrade
|
| Net Debt Issued (Repaid) | -758.81 | -7,743 | -2.9 | -2.52 | -10.16 | Upgrade
|
| Issuance of Common Stock | 24.88 | 5.26 | 214.96 | 385.52 | 12,418 | Upgrade
|
| Common Dividends Paid | -3,295 | - | - | - | - | Upgrade
|
| Other Financing Activities | -305.95 | -256.11 | -62.87 | -34.02 | -23.31 | Upgrade
|
| Financing Cash Flow | -4,335 | -7,994 | 149.19 | 348.98 | 12,385 | Upgrade
|
| Foreign Exchange Rate Adjustments | 131.31 | 77.23 | 30 | 33.11 | 35.77 | Upgrade
|
| Net Cash Flow | 21,991 | -15,518 | 15,901 | -1,736 | 3,230 | Upgrade
|
| Free Cash Flow | 5,302 | 6,069 | 1,430 | 2,794 | 3,762 | Upgrade
|
| Free Cash Flow Growth | -12.63% | 324.27% | -48.81% | -25.71% | -25.70% | Upgrade
|
| Free Cash Flow Margin | 9.44% | 10.71% | 3.95% | 6.35% | 10.86% | Upgrade
|
| Free Cash Flow Per Share | 32.18 | 36.84 | 8.69 | 16.98 | 23.77 | Upgrade
|
| Cash Interest Paid | 305.95 | 256.11 | 62.87 | 34.02 | 23.31 | Upgrade
|
| Cash Income Tax Paid | 3,538 | 3,061 | 3,109 | 4,065 | 3,114 | Upgrade
|
| Levered Free Cash Flow | 6,785 | 4,211 | 875.11 | 493.54 | 2,037 | Upgrade
|
| Unlevered Free Cash Flow | 7,048 | 4,347 | 914.4 | 514.8 | 2,055 | Upgrade
|
| Change in Net Working Capital | -1,641 | 1,294 | 3,850 | 4,163 | 4,322 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.